http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CZ-20033450-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1f80345cd7dca797683485679eb86b4e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D217-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 |
| filingDate | 2002-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_762b01f49ba8b97b97376fe0c760396a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f2969c3849b90849a8e90fbd4ca40cb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_807fe7cd363ac57318efe2af06454bfa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68831140620059869393c4a05526de1a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c9af2ea634a9f87433c1031543a6f3a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b220f20ccc2d692c70606cb6f590a80 |
| publicationDate | 2004-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CZ-20033450-A3 |
| titleOfInvention | Heterocyclic compound and its medical use |
| abstract | New tetrahydroisoquinoline-carboxylic acid compounds (I). Tetrahydroquinoline compounds of formula (I) and their salts are new. [Image] R 1H or 1-6C alkyl; R 2H, COR 3, COCR 4=CR 4R 5, COCCR 6, COCH=Cyc, aryl, 1-6C alkyl, 1-6C haloalkyl, 2-6C alkenyl, 3-8C cycloalkyl, 3-8C cycloalkyl-1-3C alkyl or optionally substituted aryl-1-3C alkyl; Cyc : 3-8C cycloalkylene; R 32-6C alkyl or 2-6C haloalkyl; R 4H or 1-4C alkyl; R 51-8C alkyl, 2-8C alkenyl, aryl or heteroaromatic; R 61-8C alkyl; Y : -ON=CR 14R 15; R 7H or 1-4C alkyl; R 85-8C alkyl, 4-8C cycloalkyl 1-4C alkylthio-1-6C alkyl, CR 9=CR 9R 10, NR 11COR 12, ZR 13or CH=Cyc; R 9, R 11, R 14H or 1-4C alkyl; R 101-6C alkyl, 1-6C haloalkyl, 2-8C alkenyl, aryl, heteroaromatic, 3-8C cycloalkyl, 3-8C cycloalkyl-1-3C alkyl, 1-4C alkoxy-1-6C alkyl, 1-4C alkylthio-1-6C alkyl or NR 9R 9-1-6C alkyl; R 121-6C alkyl or aryl; R 131-6C alkyl or aryl; Z, X : O or SR 15; ACTIVITY : Antidiabetic; Antilepic; Antiarteriosclerotic; Anorectic, Antiinflammatory; Hypoglycemic. Administration of 2-(2,4-hexadienoyl)-7-[2-(5-methyl-2-(trans-1-hepten-1-yl)oxazol-4-yl)ethoxy]-1,2,3,4-tetrahydroisoquinoline-(3S)-carboxylic acid (Ia) to db/db mice at 3 mg/kg/day orally reduced blood glucose levels by 57.2% and blood triglyceride levels by 78.1% after 2 weeks. MECHANISM OF ACTION : PPAR-Antagonist;. |
| priorityDate | 2001-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 343.